<DOC>
	<DOC>NCT00701662</DOC>
	<brief_summary>The objective of this study is to assess efficacy, safety, and convenience of purified human antibodies administered under the skin in the treatment of MMN patients.</brief_summary>
	<brief_title>A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)</brief_title>
	<detailed_description />
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients with documented clinical diagnosis and electrophysiological evidence of MMN Patients who have previously responded to intravenous immunoglobulin (IVIG) and have been on stable treatment with IVIG for at least 12 weeks prior to screening Patients treated with the equivalent of â‰¥0.4g/kg body weight (bw) IVIG per month Provision of informed consent by patient Aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) concentration &gt;2.5 times the upper normal limit (UNL) Creatinine concentration &gt;1.5 times the UNL Known allergic reactions to blood products Any skin disease interfering with the assessment of injection site reactions Any other medical condition, which in the opinion of the investigator, might interfere with successful completion of the protocol Any condition likely to interfere with the evaluation of the study drug or satisfactory conduct of the trial Participation in a study with an investigational drug within three months prior to enrolment Patients treated with the equivalent of &gt;2.0g/kg bw IVIG per month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>